Cambridge Investment Research Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.2M Buy
144,124
+536
+0.4% +$70.6K 0.04% 445
2026
Q1
$20M Buy
143,588
+3,267
+2% +$457K 0.05% 379
2025
Q4
$17.2M Sell
140,321
-21,522
-13% -$2.62M 0.05% 409
2025
Q3
$18M Sell
161,843
-1,003
-0.6% -$114K 0.05% 382
2025
Q2
$18.1M Sell
162,846
-27,927
-15% -$2.97M 0.05% 347
2025
Q1
$21.4M Buy
190,773
+38,530
+25% +$3.98M 0.07% 272
2024
Q4
$14.1M Buy
152,243
+16,375
+12% +$1.47M 0.05% 381
2024
Q3
$11.4M Sell
135,868
-42,455
-24% -$3.24M 0.04% 453
2024
Q2
$12.2M Buy
178,323
+705
+0.4% +$47K 0.05% 401
2024
Q1
$13M Sell
177,618
-42,376
-19% -$3.26M 0.05% 363
2023
Q4
$17.8M Buy
219,994
+17,774
+9% +$1.38M 0.08% 257
2023
Q3
$15.2M Buy
202,220
+64,569
+47% +$4.97M 0.07% 268
2023
Q2
$10.6M Sell
137,651
-5,255
-4% -$419K 0.05% 370
2023
Q1
$11.9M Sell
142,906
-1,016
-0.7% -$84.2K 0.06% 325
2022
Q4
$12.4M Sell
143,922
-17,588
-11% -$1.39M 0.06% 307
2022
Q3
$9.96M Buy
161,510
+5,043
+3% +$318K 0.06% 330
2022
Q2
$9.67M Buy
156,467
+5,519
+4% +$342K 0.05% 342
2022
Q1
$8.97M Buy
150,948
+1,625
+1% +$104K 0.04% 413
2021
Q4
$10.8M Sell
149,323
-3,502
-2% -$241K 0.05% 356
2021
Q3
$10.7M Sell
152,825
-6,875
-4% -$483K 0.05% 339
2021
Q2
$11M Sell
159,700
-303
-0.2% -$20.2K 0.05% 341
2021
Q1
$10.3M Buy
160,003
+4,751
+3% +$306K 0.06% 328
2020
Q4
$9.04M Sell
155,252
-3,656
-2% -$221K 0.05% 327
2020
Q3
$10M Sell
158,908
-69,040
-30% -$4.79M 0.07% 272
2020
Q2
$17.5M Sell
227,948
-29,472
-11% -$2.26M 0.13% 165
2020
Q1
$19.2M Buy
257,420
+136,590
+113% +$9.44M 0.18% 119
2019
Q4
$7.85M Buy
120,830
+15,144
+14% +$986K 0.06% 316
2019
Q3
$6.7M Sell
105,686
-8,467
-7% -$553K 0.06% 314
2019
Q2
$7.71M Sell
114,153
-22,517
-16% -$1.48M 0.07% 268
2019
Q1
$8.88M Sell
136,670
-87
-0.1% -$5.78K 0.09% 230
2018
Q4
$8.55M Sell
136,757
-10,096
-7% -$706K 0.09% 208
2018
Q3
$11.3M Sell
146,853
-8,466
-5% -$639K 0.11% 187
2018
Q2
$11M Sell
155,319
-8,907
-5% -$629K 0.12% 172
2018
Q1
$12.4M Sell
164,226
-37,696
-19% -$3M 0.14% 147
2017
Q4
$14.5M Buy
201,922
+8,351
+4% +$634K 0.17% 123
2017
Q3
$15.7M Buy
193,571
+4,028
+2% +$308K 0.21% 95
2017
Q2
$13.4M Sell
189,543
-2,135
-1% -$142K 0.2% 102
2017
Q1
$13M Buy
191,678
+57,423
+43% +$4.04M 0.22% 93
2016
Q4
$9.61M Buy
134,255
+11,333
+9% +$842K 0.18% 112
2016
Q3
$9.73M Buy
122,922
+14,341
+13% +$1.16M 0.18% 104
2016
Q2
$9.06M Buy
108,581
+4,167
+4% +$370K 0.19% 105
2016
Q1
$9.59M Buy
104,414
+2,557
+3% +$231K 0.22% 93
2015
Q4
$10.3M Buy
101,857
+6,154
+6% +$640K 0.24% 89
2015
Q3
$9.4M Buy
95,703
+11,749
+14% +$1.3M 0.27% 78
2015
Q2
$9.83M Buy
83,954
+15,468
+23% +$1.69M 0.27% 81
2015
Q1
$6.72M Buy
68,486
+14,982
+28% +$1.52M 0.19% 106
2014
Q4
$5.04M Buy
53,504
+7,561
+16% +$782K 0.16% 131
2014
Q3
$4.89M Buy
45,943
+3,158
+7% +$309K 0.14% 145
2014
Q2
$3.55M Buy
42,785
+15,243
+55% +$1.19M 0.12% 154
2014
Q1
$1.95M Sell
27,542
-1,055
-4% -$82.7K 0.07% 266
2013
Q4
$2.15M Buy
28,597
+5,668
+25% +$395K 0.09% 217
2013
Q3
$1.44M Buy
22,929
+2,976
+15% +$178K 0.06% 277
2013
Q2
$1.02M Buy
+19,953
New +$1.04M 0.05% 317

Other funds holding GILD

Cambridge Investment Research Advisors's GILD Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Gilead Sciences (GILD) stake by 0.37% in Q2 2026, buying an estimated $70.6K and bringing the position to 144,124 shares worth $18.2M. The position accounts for 0.04% of the portfolio, ranked #445.

Cambridge Investment Research Advisors first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $21.4M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cambridge Investment Research Advisors held 144,124 shares of Gilead Sciences worth $18.2M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 536 Gilead Sciences shares in Q2 2026, an estimated $70.6K.
  • Gilead Sciences made up 0.04% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #445 holding.
  • Cambridge Investment Research Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Cambridge Investment Research Advisors's Gilead Sciences position peaked at $21.4M in Q1 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.